Article

Clinical performance supports role of phakic lens

New Orleans—Results from continued follow-up of myopic eyes enrolled in the FDA clinical trial of the Verisyse phakic lens (Advanced Medical Optics) support the conclusion that the iris-fixated implant is a safe, effective, and very useful adjunct in a refractive surgery practice, said Richard L. Lindstrom, MD, at a session during the International Society of Refractive Surgery of the American Academy of Ophthalmology annual meeting.

"We continue to be very pleased with the refractive and visual outcomes and have found complications to be minimal and manageable," commented Dr. Lindstrom, adjunct professor emeritus, department of ophthalmology, University of Minnesota, and founder, Minnesota Eye Consultants, Minneapolis.

He presented results from the first 157 eyes of 83 patients undergoing implantation. The preoperative myopic treatment range was between -5 and -20 D (mean -12 D), and the patients ranged in age from 21 to 53 years (mean 40 years). One hundred forty-one eyes were seen at 1 year, and 71 eyes had reached the 3-year follow-up visit.

Best-corrected visual acuity was 20/40 or better in 99.3% of eyes at 1 year and in all eyes evaluated after 3 years.

The predictability analyses showed that at both 1 and 3 years, about 70% of eyes were corrected to within 0.5 D of target refraction.

"These results are consistent with the predictability that can be achieved with any type of lens implant given dependence on the vertex distance of the lens implant," Dr. Lindstrom said. "However, the participants within the clinical trial were also allowed to have up to 2.5 D of astigmatism, which could only be treated by moving the incision to the steeper meridian."

That technique, use of corneal relaxing incisions, or excimer laser enhancement after the eye has healed from the phakic IOL surgery are now options for managing significant astigmatism or fine-tuning spherical power in patients undergoing implantation of the Verisyse lens since it became commercially available. Secondary surgery with relaxing incisions or laser enhancement are also being offered to correct residual astigmatism in patients who were participants in the FDA trial.

"Interestingly, we are finding that most of our patients with high myopia with spherical errors of about -12 D or greater are usually pretty satisfied with their outcomes despite having some mild residual ametropia, and so our enhancement rate is lower than we anticipated," he said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.